Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL) Meeting Abstract
| Authors: | Weber, J. S.; Larkin, J. M. G.; Schadendorf, D.; Wolchok, J. D.; Wagstaff, J.; Dummer, R.; Hogg, D.; Guidoboni, M.; Sosman, J. A.; Chmielowski, B.; Gerritsen, W.; Bhore, R.; Walker, D.; Gonzalez, R. |
| Abstract Title: | Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 481s |
| Language: | English |
| ACCESSION: | WOS:000411932203166 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.9523 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9523 -- Source: Wos |
